Aldeyra 公布 ADX-629 酒精相關肝炎 Phase 2 頂線正面結果

ADX-629 達成主要目標，在 4 人 Phase 2 試驗中顯示 MELD 評分、三酸甘油酯及 CRP 相較基線有統計學顯著改善。Aldeyra 將停止 ADX-629 後續開發，並將資源轉向下一代 RASP 調節劑 ADX-248 及 ADX-246，現金流動性延長至 2027 年下半年。

關鍵事實

申報時間: 2025年10月28日上午11:00
事件: 主要結果 (Topline)
方向: 正面
公司: ALDXAldeyra
資產: ADX-629
來源: SEC 8-K
可信度: 有出處
患者: 4
現金跑道: H2 2027
CRP 水平 p 值: <0.0001
MELD 評分 p 值: 0.001
三酸甘油酯水平 p 值: <0.0001

來源摘錄

EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules • Relative to Baseline, Signal-Finding Molecule ADX‑629 Demonstrated Statistically Significant Improvement in Liver Function in Patients with Alcohol-Associated Hepatitis • RASP Modulator Product Candidate Pipeline Focused on ADX‑248 and ADX‑246 for Dermatologic, Metabolic, and Retinal Immune-Mediated Diseases • Cash Runway Extended into the Second Half of 2027 Lexington, Mass. October 28, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed t

SEC 8-K